Synlett 2020; 31(04): 327-333
DOI: 10.1055/s-0039-1690792
account
© Georg Thieme Verlag Stuttgart · New York

Development of a Divergent Route to Erythrina Alkaloids

Sebastian Clementson
a   Molecular Discovery and Innovation, H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark
b   Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark   Email: jesper.kristensen@sund.ku.dk
,
Mikkel Jessing
a   Molecular Discovery and Innovation, H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark
,
Paulo J. Vital
,
b   Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark   Email: jesper.kristensen@sund.ku.dk
› Author Affiliations
We are grateful to the Innovationsfonden (Innovation Fund Denmark, Grant No. 7038-00149B) for generous support of this project.
Further Information

Publication History

Received: 19 December 2019

Accepted after revision: 02 January 2020

Publication Date:
23 January 2020 (online)


Abstract

Erythrina alkaloids were identified at the end of the 19th century and today, more than 100 members of the erythrinane family have been isolated. They are characterized by a unique tetracyclic, α-tertiary spiroamine scaffold. Herein we detail our efforts towards the development of a divergent enantioselective synthesis of (+)-dihydro-β-erythroidine (DHβE) – one of the most prominent members of this intriguing family of natural products.

1 Introduction

2 Synthetic Strategy

2.1 First Generation

2.2 Second Generation

2.3 Third Generation

2.3.1 Radical Endgame

2.3.2 Completion of the Total Synthesis

3 Conclusion